Neumora Therapeutics, Inc. (NMRA)
2.07
-0.12
(-5.48%)
USD |
NASDAQ |
Dec 09, 16:00
2.08
+0.01
(+0.48%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 345.87M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -78.72% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 2.617 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.152 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA. |
| URL | http://www.neumoratx.com |
| Investor Relations URL | https://ir.neumoratx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 02, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA. |
| URL | http://www.neumoratx.com |
| Investor Relations URL | https://ir.neumoratx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 02, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |